Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

CAMBRIDGE, England, November 21, 2011 /PRNewswire/ --

Phase I Single Dose Study Data Demonstrate Ideal Pharmacokinetic Profile and Excellent Safety and Tolerability

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

The trial is a randomised, placebo controlled Phase I study to investigate the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944 in both young and elderly volunteers. CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis. The study is expected to conclude in 2Q 2012.

The first human single ascending dose Phase I study with orally administered CNV2197944 was recently completed. CNV2197944 was shown to be well absorbed, with an ideal pharmacokinetic profile for the target indication of chronic pain. The compound was well tolerated, with an excellent safety profile.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, commented: "We are really excited to be advancing on schedule to a multiple ascending dose study with this novel, first-in-class treatment for chronic pain.  The data we have seen so far gives us great confidence that CNV2197944 will be a safe and effective long term treatment for chronic pain."

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... Ryan Carfley , Managing Partner at Personify ... Bryan Hamilton, the publisher of the Triangle Business Journal, and ... Research Triangle region of North Carolina. , Just a few ... include the role of social media in recruitment, recruiting ... the unique role that Millennials play in the workplace today. ...
(Date:10/27/2014)... 27, 2014 The “Molecular Diagnostic ... Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User ... Software) - Global Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
(Date:10/27/2014)... Janssen Biotech, Inc. and the Crohn,s ... the launch of Get Your Full ... designed to provide resources for people living with ... of nutrition and appropriate therapy in managing IBD. ... with this release, please click: http://www.multivu.com/players/English/7261131-janssen-ccfa-get-your-full-course-for-ibd-wellness-with-sunny-anderson/ ...
(Date:10/25/2014)... Angeles, California (PRWEB) October 23, 2014 ... ), a specialty pharmaceutical company devoted to bringing ... out-licensing partnerships in 2015. , ViaDerma has developed ... which allows for rapid mass transfer of pharmaceutical ... the body to provide immediate localized therapy. The ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... , ... transfer has traditionally been a fast but inefficient method , ... buffer system, transfer efficiency can be greatly increased. In protein , ... elution of the proteins , from a gel and ...
... Introduction , Amplification of ... highly sensitive method capable of copying millions of DNA molecules from , ... extreme sensitivity of this method, , any carry-over ... or extra bands. Carry-over contamination can be avoided by using positive , ...
... Luis A Ugozzoli, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive,Hercules, ... Introduction , ... greatly refined since its advent 16 years ago. Several improvements , ... the way PCR is performed today relative to earlier protocols. ...
Cached Biology Technology:Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 2Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 3Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 4Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light 2Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light 3The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 2The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 3The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 4The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 5The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 6The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 7The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 8
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
(Date:10/30/2014)... 2014 – Bacteria in the gastrointestinal tract fulfill ... Yet, these same bacteria can induce strong inflammatory ... the gut and enter the bloodstream. , Although ... the body, chronic or systemic inflammation is linked ... established the involvement of inflammatory processes in the ...
(Date:10/30/2014)... , Oct. 29, 2014  Securus Technologies, ... justice technology solutions for public safety, investigation, ... has deployed exciting enhancements to its THREADS™ ... to provide actionable intelligence and focused leads ... to drive technological innovation through identifying and ...
Breaking Biology News(10 mins):Identifying the source of stem cells 2Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2
... at the Texas Biomedical Research Institute in San Antonio ... of "bad" cholesterol. This discovery could lead to the ... heart disease., "Our findings are important because they provide ... reduce heart disease risk in humans," said Laura Cox, ...
... Dr. Philippe Wernet, chemist Prof. Dr. Athina Zouni of Humboldt ... Accelerator Laboratory and Dr. Junko Yano of the Lawrence Berkeley ... In spite of the fact that all aerobic organisms ... Because as part of photosynthesis, green plants, algae, and cyanobacteria ...
... predicts their political opinions on economic redistribution, according ... , a journal of the Association for Psychological ... psychological scientists Michael Bang Petersen of Aarhus ... Santa Barbara believe that the link may ...
Cached Biology News:4 genes indentified that influence levels of 'bad' cholesterol 2Snap shots of 1 of life's central processes 2Political motivations may have evolutionary links to physical strength 2
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
... Reader is Cellomics‘ latest product ... Cell-based Screening". The KineticScan Reader ... do both temporal and high-resolution ... dynamic distribution and activity of ...
... Introduction of a protein into cells ... cell signaling pathways, apoptotic pathways, and transcription ... for studying the effects of a specific ... transfect the protein directly into the cell. ...
... is an innovative reagent for highly efficient ... of living cells. Unlike DNA transfection, with ... amount and timing of exogenous proteins in ... can now be studied. Real time ...
Biology Products: